Autoantibodies in Early Detection of Breast Cancer.

In spite of the progress made in treatment and early diagnosis, breast cancer remains a major public health issue worldwide. Although modern image-based screening modalities have significantly improved early diagnosis, around 15% to 20% of breast cancers still go undetected. In underdeveloped countries, lack of resources and cost concerns prevent implementing mammography for routine screening. Noninvasive, low-cost, blood-based markers for early breast cancer diagnosis would be an invaluable alternative that would complement mammography screening. Tumor-specific autoantibodies are excellent biosensors that could be exploited to monitor disease-specific changes years before disease onset. Although clinically informative autoantibody markers for early breast cancer screening have yet to emerge, progress has been made in the development of tools to discover and validate promising autoantibody signatures. This review focuses on the current progress toward the development of autoantibody-based early screening markers for breast cancer.<b>See all articles in this <i>CEBP Focus</i> section, "NCI Early Detection Research Network: Making Cancer Detection Possible."</b>

Anderson KS, LaBaer J, Rauf F

32994341

Cancer Epidemiol Biomarkers Prev, 2020, 29 (12)

Version 5.1.0